Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
|
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 50 条
  • [1] Advances in targeting HER2-positive breast cancer
    Harbeck, Nadia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 55 - 59
  • [2] Dissecting the biological heterogeneity of HER2-positive breast cancer
    Schettini, Francesco
    Prat, Aleix
    BREAST, 2021, 59 : 339 - 350
  • [4] Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
    Holloway, Ryan W.
    Marignani, Paola A.
    CANCERS, 2021, 13 (12)
  • [5] Heterogeneity of genomic profile in patients with HER2-positive breast cancer
    Bo Chen
    Zhang, Guochun
    Wei, Guangnan
    Wang, Yulei
    Guo, Liping
    Lin, Jiali
    Kai Li
    Mok, Hsiaopei
    Li Cao
    Ren, Chongyang
    Wen, Lingzhu
    Jia, Minghan
    Li, Cheukfai
    Ting Hou
    Han Han-Zhang
    Jing Liu
    Balch, Charles M.
    Ning Liao
    ENDOCRINE-RELATED CANCER, 2020, 27 (03) : 153 - 162
  • [6] Molecular heterogeneity of HER2-positive breast cancer: Prognosis and prediction
    Kreklau A.
    Aktas B.
    Der Gynäkologe, 2018, 51 (10): : 870 - 877
  • [7] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [8] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [9] Targeting HER2-positive breast cancer: advances and future directions
    Swain, Sandra M.
    Shastry, Mythili
    Hamilton, Erika
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (02) : 101 - 126
  • [10] A systematic review of dual targeting in HER2-positive breast cancer
    Kumler, Iben
    Tuxen, Malgorzata K.
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 259 - 270